Grants and Contributions:
Title:
Development of a novel mRNA therapy encoding a hepatokine
Agreement Number:
995579
Agreement Value:
$75,000.00
Agreement Date:
Sep 15, 2022 - Mar 31, 2023
Description:
This project will involve the development of a proprietary lipid nanoparticle (LNP)-mRNA technology for the safe and effective delivery of mRNA encoding the hepatokine Fibroblast Growth Factor 21 (FGF21) as a hepatic gene therapy to promote weight loss in a diet-induced obesity models.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6T 1Z3
Reference Number:
172-2022-2023-Q3-995579
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
714010279
Recipient Type:
For-profit organization
Recipient's Legal Name:
NanoVation Therapeutics Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710